Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation
Authors
Keywords
-
Journal
LIVER TRANSPLANTATION
Volume 18, Issue 9, Pages 1053-1059
Publisher
Wiley
Online
2012-06-18
DOI
10.1002/lt.23482
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon
- (2012) Josh Levitsky et al. GASTROENTEROLOGY
- 14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN
- (2012) F. Suzuki et al. JOURNAL OF HEPATOLOGY
- 1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3
- (2012) M. Sulkowski et al. JOURNAL OF HEPATOLOGY
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin
- (2011) Jee Eun Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men
- (2011) Jennifer C. Lai et al. HEPATOLOGY
- Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus
- (2011) Varun Garg et al. HEPATOLOGY
- Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
- (2011) Richard E. Nettles et al. HEPATOLOGY
- Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
- (2011) Robert A. Fridell et al. HEPATOLOGY
- Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
- (2011) Kazuaki Chayama et al. HEPATOLOGY
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation
- (2010) P. Guillouche et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab
- (2010) Maria L Alcaide et al. CLINICAL TRANSPLANTATION
- Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients
- (2010) Nazia Selzner et al. JOURNAL OF HEPATOLOGY
- Post-liver transplant cholestatic hepatitis C: A systematic review of clinical and pathological findings and application of consensus criteria
- (2010) Tarun K. Narang et al. LIVER TRANSPLANTATION
- Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients with Recurrent Hepatitis C Infection
- (2008) B. J. Veldt et al. AMERICAN JOURNAL OF TRANSPLANTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search